Vadastuximab Talirine + Hypomethylating Agents Active and Well Tolerated in Untreated Older Patients With AML

Slideset - In this phase I trial, vadastuximab talirine plus HMA was active in higher-risk patient subsets, including patients with advanced secondary AML and those older than 75 years of age.

Source: Clinical Care Options Leukemia - December 8, 2016 Category: Hematology Source Type: research